Does Lurbinectedin Interact with Other Medications?
Yes, lurbinectedin (brand name Zepzelca) alters the effects of co-medications primarily through its metabolism by CYP3A enzymes in the liver. It acts as a time-dependent inhibitor of CYP3A4/5 and induces CYP2B6, CYP2C9, and CYP2C19, potentially changing drug levels and efficacy [1][2].
Which Drugs Are Most Affected?
- CYP3A substrates: Lurbinectedin increases exposure to sensitive substrates like midazolam (by 30-60%) or simvastatin. Avoid strong CYP3A inducers (e.g., rifampin, carbamazepine) during treatment and for 5 days after, as they lower lurbinectedin levels by up to 60% [1][2].
- CYP3A inhibitors: Strong inhibitors (e.g., ketoconazole, itraconazole) raise lurbinectedin exposure; monitor or adjust doses [2].
- Probes for induction: Lurbinectedin reduces omeprazole (CYP2C19) by 20-30% and increases warfarin-like effects via CYP2C9 induction [2].
- Common co-meds in cancer care: Adjust doses for dexamethasone (CYP3A substrate), anticoagulants, or statins [1].
No major changes to P-gp or BCRP substrates at clinical doses [2].
How Should Clinicians Manage Interactions?
Separate administration by 4 hours from CYP3A modulators. Use tools like the University of Liverpool interaction checker for specifics. Monitor for toxicity (e.g., myelosuppression) or reduced efficacy in polypharmacy [1][3].
Patient Experiences and Risks
Patients report heightened side effects like nausea or fatigue when combined with CYP3A-altering meds (e.g., PPIs, antifungals). Severe risks include QT prolongation with certain antiemetics or bleeding with warfarin [1][4].
Alternatives if Interactions Are a Concern?
Switch to drugs with minimal CYP3A reliance, like topotecan for SCLC, or time doses apart. No biosimilars yet; patents on lurbinectedin formulations extend to 2032+ per DrugPatentWatch.com [5].
[1]: Zepzelca Prescribing Information, Jazz Pharmaceuticals (FDA label, 2023).
[2]: FDA Drug Approval Package for Lurbinectedin, clinical pharmacology review (2020).
[3]: Lexicomp Drug Interactions Database, Wolters Kluwer (accessed 2024).
[4]: Post-marketing reports via FAERS database, FDA (2020-2024).
[5]: DrugPatentWatch.com, lurbinectedin patent dashboard (https://www.drugpatentwatch.com/p/tradename/ZEPZELCA).